Lurbinectedin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Lurbinectedin
Accession Number
DB12674
Type
Small Molecule
Groups
Investigational
Description

Lurbinectedin has been used in trials studying the treatment of Solid Tumors, Breast Cancer, Ovarian Cancer, Metastatic Sarcoma, and Neuroendocrine Tumors, among others.

Structure
Thumb
Synonyms
Not Available
External IDs
PM-01183 / PM01183
Categories
UNII
2CN60TN6ZS
CAS number
497871-47-3
Weight
Average: 784.88
Monoisotopic: 784.277814807
Chemical Formula
C41H44N4O10S
InChI Key
YDDMIZRDDREKEP-HWTBNCOESA-N
InChI
InChI=1S/C41H44N4O10S/c1-17-11-20-12-25-39(48)45-26-14-52-40(49)41(38-22(9-10-42-41)23-13-21(50-5)7-8-24(23)43-38)15-56-37(31(45)30(44(25)4)27(20)32(47)33(17)51-6)29-28(26)36-35(53-16-54-36)18(2)34(29)55-19(3)46/h7-8,11,13,25-26,30-31,37,39,42-43,47-48H,9-10,12,14-16H2,1-6H3/t25-,26-,30+,31+,37+,39-,41+/m0/s1
IUPAC Name
(1R,2R,3R,11S,12S,14R,26R)-5,12-dihydroxy-6,6'-dimethoxy-7,21,30-trimethyl-27-oxo-2',3',4',9'-tetrahydro-17,19,28-trioxa-24-thia-13,30-diazaspiro[heptacyclo[12.9.6.1^{3,11}.0^{2,13}.0^{4,9}.0^{15,23}.0^{16,20}]triacontane-26,1'-pyrido[3,4-b]indole]-4(9),5,7,15(23),16(20),21-hexaen-22-yl acetate
SMILES
COC1=CC=C2NC3=C(CCN[C@]33CS[C@H]4[C@H]5[C@@H]6N(C)[C@@H](CC7=C6C(O)=C(OC)C(C)=C7)[C@H](O)N5[C@@H](COC3=O)C3=C4C(OC(C)=O)=C(C)C4=C3OCO4)C2=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
57327016
PubChem Substance
347828878
ChemSpider
32701856

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentAdvanced Solid Tumors2
1CompletedTreatmentEndometrial Adenocarcinomas / Neuroendocrine Tumors / Small-cell Lung Cancer With Less Than 2 Prior Cytotoxic-containing Lines of Therapy / Small-cell Lung Cancer With Less Than 2 Prior Cytotoxic-containing Lines of Therapy)1
1CompletedTreatmentMajor Advanced Solid Tumors Other Than Colorectal1
1CompletedTreatmentMalignant Neoplasm of Pancreas / Metastatic Breast Cancer (MBC) / Metastatic Colorectal Cancers / Unresectable Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC)1
1CompletedTreatmentSpecific Advanced Solid Tumors1
1RecruitingTreatmentAdvanced Solid Tumors1
1, 2RecruitingTreatmentAdvanced Solid Tumors / Cancer of the Ovary / Cancer, Advanced / Cancer, Breast / Endometrial Cancers1
2Active Not RecruitingTreatmentAdvanced Solid Tumors1
2Active Not RecruitingTreatmentMalignant Pleural Mesothelioma, Advanced1
2Active Not RecruitingTreatmentMetastatic Sarcoma1
2CompletedOtherTumors, Solid1
2CompletedTreatmentCancer, Breast1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
3Active Not RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
3CompletedTreatmentCancer of the Ovary1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0646 mg/mLALOGPS
logP2.65ALOGPS
logP4.52ChemAxon
logS-4.1ALOGPS
pKa (Strongest Acidic)9.35ChemAxon
pKa (Strongest Basic)7.2ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count11ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area164.28 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity205.9 m3·mol-1ChemAxon
Polarizability81.83 Å3ChemAxon
Number of Rings10ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as harmala alkaloids. These are compounds with a structure based on harmaline, harmine, harmalol, harman or a derivative of those parents. These parents are beta-carbolines, consisting of a pyrimidine fused to the pyrrole moiety of an indole to form a pyrido[3,4-b]indole.
Kingdom
Organic compounds
Super Class
Alkaloids and derivatives
Class
Harmala alkaloids
Sub Class
Not Available
Direct Parent
Harmala alkaloids
Alternative Parents
Beta carbolines / Benzazocines / Tetrahydroisoquinolines / 3-alkylindoles / Alpha amino acids and derivatives / Benzodioxoles / Anisoles / 1-hydroxy-4-unsubstituted benzenoids / Alkyl aryl ethers / N-methylpiperazines
show 17 more
Substituents
Harman / Pyridoindole / Beta-carboline / Benzazocine / Tetrahydroisoquinoline / Alpha-amino acid or derivatives / 3-alkylindole / Benzodioxole / Indole or derivatives / Indole
show 39 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 17:34 / Updated on June 04, 2019 07:41